ASCO 2023

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

From PENELOPE-B to SURVIVE

Practice changing or not quite yet?

Ribociclib improves iDFS

Early follow-up shows clear benefit

Response adapted, chemotherapy-free option in HER2+ EBC

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

Can we preserve our patients form chemotherapy?

First data with adjuvant ribociclib

Palbociclib after Palbociclib might not be the best option

My EBC highlights from ASCO23

10 years update on ShortHER

TILs in HER2+ disease - prognostic, but not enough to deescalate

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

SOC of ovarian ablation confirmed in meta-analysis.

A challenge for clinical management

Discussions on CDK4/6 inhibitors in EBC

Ribociclib has arrived in the adjuvant setting

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

TILs are prognostic but not predictive in HER2+ EBC

Ovarian function - Ovarian suppression not necessary in young patients?

Young patients benefit from ovarian suppression

De-escalation of CT for early BC

1/3 of patients with HER2+ in future without chemotherapy?

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

Another proof of efficacy of immunotherapy in advanced TNBC

More CDK4/6 options for EBC patients

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Palbociclib después de Palbociclib podría no ser la mejor opción

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Czy wystarczy, aby zmienić standardy?

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

Primele date cu ribociclib adjuvant

Eine Herausforderung für das klinische Management

I miei punti salienti di ASCO23

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

NATALEE nicht überraschend aber überzeugend positiv

Von PENELOPE-B zur SURVIVE

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

SOC der ovarialen Ablation in der Metaanalyse bestätigt

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

Eine Herausforderung für viele Patienten, wenig Doktoren

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

The start of precision medicine in HR+ breast cancer

What is the optimal therapie sequence for HR+ MBC patients?

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

E-Health Applications in Oral Cancer Therapy

Continued OS benefit for Sacituzumab Govitecan

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

Mises à jour sur les ADC dans le cancer du sein métastatique

CDK4/6i in first line and beyond & Biomarkers

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

The value of eHealth

Update ADC efficacy

Metastasis-directed for prostate cancer

AI for prediction in local prostate carcinoma

DEAR trial: real-world comparator analyses of ARIs

Part 1: Important update on testosterone-recovery

ARASEC: ADT + Daralutamide for mHSPC

Reassuring real-world data!

TALAPRO-2: Results and controversies

PAPR-inhibitors: Patient-selection matters!

Intensified or de-intensified therapy in mHSPC

Confirming results for PARPi in mCRPC

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Part2: Important update on testosterone-recovery

PRL-02: Intramuscular arbiraterone

Over-staging of bone scan compared with PSMA PET/CT

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

PEACE 1 - results and controversies

Intensifierad eller de-intensifierad behandling vid mHSPC?

PARP-inhibitors: La selección de pacientes es importante

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

What is your preferred sequence in 1st line treatment and how you treat after progress?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The beginning of a new era in urothelial cancer?!

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Extent of lymphadenectomy in cystectomy

Targeted therapies in advanced urothelial cancer: The renaissance?!

New SoC option for metastatic bladder cancer

FGFR inhibition

New standard for MIBC

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

The efficacy of FGFR targeting

Update EV/Pembro, Avelumab Maintenance

Non ccRCC: how should we treat patients today?

Primary endpoint not reached: what do we learn from CONTACT-03 results?

The impact of microbiome and supplements on therapy efficacy

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

Update and take home message of 1st Line mRCC

IO rechallenge in mRCC

New standard for 2nd line RCC?

New data non ccRCC

1st Line therapy RCC: which combination to choose?

Long-term follow-up for IO/TKI in mRCC

News from the adjuvant

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

A new standard of care for operated patients with eGFRmut adenocarcinoma

Adjuvant and neoadjuvant strategies in resectable NSCLC

ADAURA - Discussion closed?

Another neoadjuvant chemo/IO option

Adjuvant IO in KRASm patients

Induction options in the perioperative setting

A chemo-free preop. IO strategy?

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

An imperfect analysis, but perfect results

A new standard of care

More options in the perioperative setting

CheckMate 9LA: 4‑year clinical update

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

OS benefit from EGFR receptor TKI

Perioperative treatment

Role of periopertative IO confirmed

Confirmation of neoadjuvant immunotherapy

ADAURA - results and controversies

EGFR testing necessary in the adjuvant setting

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Rolle der periopertativen IO bestätigt

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

Más opciones en el entorno perioperatorio

ADAURA- discussie gesloten?

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Does ADC + chemo + IO replace the existing concepts?

TTF-treatment requires further studies

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Sotorasib: clear clinical benefit, but short follow-up time

Zorifertinib: an option when osimertinib is not available

Update on KRASG12Cm treatment options - how to proceed?

CORRELATE - a real world analysis

LUNAR: TTF medical device shows OS-benefit, but more information needed

IO in EGRF positive patients post TKI

Stopping treatment is ok

ADC + ICI ± Pt-CT in patients with aNSCLC

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Treatment strategies in SCLC

Hyperfractionated radiotherapy for SCLC

A positive trial with no impact

Can we incoporate biomarkers in SCLC treatment?

More BiTEs, more possibilities

Stratégies de traitement dans le SCLC

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

Immune checkpoint inhibitors in malignant mesothelioma

No practice-changing data in mesothelioma, other studies to await

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom